The BMP-9/BMP-10/ALK1 pathway is a promising target for anti-angiogenic cancer therapy and with dalantercept (previously known as ACE-041) a new drug is now being tested, displaying promising antitumor activity in patients with advanced refractory cancer of diverse origins including liver [92], and multiple phase II studies will follow soon. Here, GDF2 is linked to cancer.